Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Biberach – page 41

668 clinical trials in Biberach, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Biberach at a glance
668
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

668 trials in Biberach

Open in trial search

Study of Chemotherapy with Osimertinib in Non-Small Cell Lung Cancer Patients Who Have Progressed After Initial Osimertinib Treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study of Copanlisib with Rituximab and CHOP for Untreated Diffuse Large B-Cell Lymphoma in Patients Aged 18-80

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Universitaetsklinikum Muenster AöR

Study of Pembrolizumab with Lenvatinib after Chemoradiation Treatment in Patients with Locally Advanced Head and Neck Cancer who are PD-L1 Positive

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Universitaet Des Saarlandes

Study on the Safety and Efficacy of CLS12311 and Autologous Red Blood Cells for Patients with Relapsing Remitting Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:CLS12311
  • Sponsor:Cellerys AG

Cholangiocarcinoma+3

Not recruiting

Study of Durvalumab, Tremelimumab, and Capecitabine for Patients with Biliary Tract Cancer in an Adjuvant Setting

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study of Efgartigimod PH20 SC for Adults with Thyroid Eye Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Malignant melanoma

Not recruiting

Study on Fianlimab and Cemiplimab for Adults with Resectable Stage III and IV Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Breast cancer+4

Not recruiting

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Renal cell carcinoma

Not recruiting

Study on Atezolizumab and Cabozantinib for Patients with Advanced Renal Cell Carcinoma After Tumor Progression Post-Immune Checkpoint Inhibitor Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Adenocarcinoma gastric+1

Not recruiting

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Obesity

Not recruiting

Study of Setmelanotide for Patients with Obesity Due to Specific Genetic Variants

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Setmelanotide
  • Sponsor:Rhythm Pharmaceuticals Inc.

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Biberach

What the registry says about research in the country

01 Eye Diseases and Related Research

In Biberach An Der Riss, much of the clinical trial activity is connected to eye diseases and broader investigational research in healthy volunteers. The studies are focused on understanding how new treatments are absorbed, how food affects them, and how they interact with other medicines.

  • Research involving Eye Diseases and unspecified disease areas
  • Studies in healthy volunteers and otherwise healthy participants
  • Trials exploring pharmacokinetics and medicine interactions
  • Work aimed at improving treatment use and safety for future care

These trials help clarify how candidate therapies behave in the body and support the development of better treatment options.

02 Pharmacokinetic Studies

A major part of the research landscape centers on pharmacokinetic trial work, especially in healthy people. These studies are designed to see how medicines are absorbed, distributed, and influenced by food or other drugs.

  • Testing how different formulations are taken up in the body
  • Checking the effect of food on medicine exposure
  • Evaluating possible drug-drug interactions
  • Supporting the safe development of new oral therapies

The goal is to build a clearer picture of how investigational medicines behave before wider clinical use.

03 Healthy Volunteer Trials

Many of the studies in this city involve healthy volunteer trial designs, which are used to test safety, tolerability, and how the body responds to new compounds. This research is essential for early evaluation of promising medicines.

  • Assessing how well new treatments are tolerated
  • Comparing tablet and injection-style formulations
  • Measuring exposure changes with common co-medications
  • Generating data that supports further clinical development

The emphasis is on careful observation of how healthy participants respond to study medicines.

04 Metabolic and Cardiovascular Research

Some trials also address broader metabolic and cardiovascular interests, including medicines studied for body weight-related conditions and heart effects. These projects aim to understand both benefit and safety across different formulations.

  • Research on therapies related to obesity and metabolism
  • Studies of heart-related effects and medicine exposure
  • Comparisons of separate versus combined medicine use
  • Support for better treatment planning in chronic disease care

This area reflects a wider effort to refine new treatments for complex health conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.